NKTX Aug 2024 17.500 put
| Previous close | 8.70 |
| Open | 8.70 |
| Bid | 9.90 |
| Ask | 10.40 |
| Strike | 17.50 |
| Expiry date | 2024-08-16 |
| Day's range | 8.70 - 8.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 78 |
GlobeNewswireNkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for NKX019 for the treatment of systemic sclerosis, myositis and vasculitis Clinical data from Ntrust-1 and Ntrust-2 planned for 2025 SOUTH SAN FRANCISCO, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies,
- GlobeNewswire
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
Senior R&D leader brings extensive expertise in immunology, clinical development and translational scienceSOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies today announced that translational immunology expert George Vratsanos, M.D., FACR, is joining its board of directors. Dr. Vratsanos currently serves as Chief Medical Officer and Head of R&D for Jnana Th
Simply Wall St.Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
